

Supplemental Information for Q1 2020

Intuitive Surgical, Inc. (the “Company”) is presenting certain procedure volume information to provide investors with a better understanding of the impact of the COVID-19 pandemic on the Company’s business. The Company believes that the magnitude of the impact of the COVID-19 pandemic on the Company’s business differs by geography, and in regions like the United States and certain European countries, where COVID cases continue to increase, da Vinci procedure volume could decline below the levels experienced during the last half of March 2020.

The Company believes that the recovery of procedure volume in China demonstrates that although elective surgery may be deferred, the need for surgery is durable in the long-term. However, we cannot assure you that procedure volume will continue to recover in China and other early impacted countries, as these countries may experience a recurrence of COVID-19. We also cannot predict that other countries will see recovery similar to that experienced in China, as geographies are impacted differently and the timing of recovery depends on multiple factors, including economic conditions, procedure mix, and the policies of the different countries.

Procedure reporting involves estimates and judgments and may be impacted by various factors, including changes in treatment modalities, hospital and distributor reporting behavior, and system internet connectivity. Such estimates and judgments are also susceptible to algorithmic or other technical errors. In addition, the relationship between number of da Vinci procedures and our revenues may fluctuate from period to period, and da Vinci procedure volume growth may not correspond to an increase in revenue. The number of da Vinci procedures are not intended to be considered in isolation or as a substitute for, or superior to, revenue or other financial information prepared and presented in accordance with GAAP.


Because of the high degree of uncertainty caused by COVID-19 pandemic, we are providing this supplemental information to help investors assess the performance of our business in unprecedented times. We undertake no obligation to publicly update or release any revision to this information.

Forward-Looking Statements

Except for historical information, this presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning the potential impact of COVID-19 on the Company's business, the strength of our long-term fundamentals, and the potential decline of procedure volume; and any statements using the terms "could," "believe," "expect," "outlook," "should," "will" "predict" or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company's actual results to differ materially from those anticipated. These forward-looking statements should, therefore, be considered in light of various important factors, including, but not limited to, the following: the ability of the Company to obtain accurate procedure volume in the midst of the COVID-19 pandemic, the risk that the COVID-19 pandemic could lead to material delays and cancellations of procedures, curtailed or delayed capital spending by hospitals and disruption to our supply chain, closures of our facilities, delays in surgeon training, delays in gathering clinical evidence, diversion of management and other resources to respond to the COVID-19 pandemic; the evaluation of the risks of robotic-assisted surgery in the presence of infectious disease, the impact of global and regional economic and credit market conditions on healthcare spending; the risk that the COVID-19 virus disrupts and causes economies in our key markets to enter prolonged recessions and other risk factors under the heading "Risk Factors" in the Company's report on Form 10-K for the year ended December 31, 2019, as updated by the Company's other filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this presentation. The Company undertakes no obligation to publicly update or release any revisions to these forward-looking statements, except as required by law.

Worldwide procedures by week

Weeks 2–13



All procedures: Weekly procedures % of Normalized run-rate

Weeks 2–13

